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In Brief Mancio-Silva et al. show that nucleic acid-mediated silencing of primary human hepatocytes can be leveraged in an in vitro engineered human liver model to fine-tune metabolism and to assess safety and efficacy of RNAi-based therapeutics.
INTRODUCTION
The liver plays an important role in protecting the organism from various insults, including drugs, chemicals, and pathogens. This protective ability stems from a wide variety of enzymes expressed by hepatocytes that catalyze the oxidation, reduction, and hydrolysis (phase 1) and/or conjugation (phase 2) of functional groups, leading to xenobiotic conversion into metabolites that can be efficiently eliminated from the body. During this detoxification process, some drugs and chemical molecules are converted into highly reactive toxic metabolites that can cause severe cellular damage. Drug-induced liver injury (DILI) remains a leading cause of drug candidate failure in preclinical and clinical trials, as well as a common cause for drugs to be withdrawn from the market after approval (Regev, 2014) . In other situations, an otherwise effective parental drug compound can be inactivated by the metabolism process, negating its therapeutic impact, with or without the generation of a toxic by-product (Chen et al., 2018; de Man et al., 2018; Persiani et al., 2006) . Thus, accurate prediction of drug metabolism and the mechanism of toxicity in human liver is a critical task to establish an efficient drug discovery pipeline. A major limitation in this area is the lack of in vitro or animal models that faithfully recapitulate human hepatic-specific functions. Species differences in drug metabolism, drug targets, and pathophysiology are factors that limit the utility of animals for preclinical assessments (Olson et al., 2000) . The alternative in vitro liver models include human hepatocarcinoma cell lines and primary hepatocytes, yet these experimental tools also present major challenges. Specifically, hepatocarcinoma cell lines are of limited utility due to uncontrolled proliferation and abnormal hepatic-specific function observed in most cell lines, while primary hepatocytes, which are considered the gold standard to study metabolism and predictive toxicity, are short lived in culture (Soldatow et al., 2013) , and sandwich-cultured hepatocytes, which have an extended survival time, have been shown to have altered metabolic function (Jacobsen et al., 2011; Mathijs et al., 2009) .
In an effort to overcome the rapid loss of metabolic function observed in cultured primary human hepatocytes, remarkable progress has been made in the bioengineering field to develop technologies that support long-term phenotypic function of in vitro cultured primary hepatocytes Underhill and Khetani, 2017) . Engineered liver systems of primary human hepatocytes are available in a variety of platform models, but typically rely on a single hepatocyte donor, which might be problematic due to under sampling the genetic variation seen in phase 1 and phase 2 enzymes across individuals of different genotypes (Kratochwil et al., 2017; Rogue et al., 2012 ). This population-based heterogeneity has been shown to account for much of the observed clinical variability in drug effectiveness and risk of adverse events (Zanger and Schwab, 2013 ). An attractive alternative would be the capacity to perform drug screens in higher versus relatively low-metabolizing donors, which could ideally be achieved via genetic engineering of otherwise identical hepatocytes in order to tune potential drug metabolism. Furthermore, accurate prediction of potential toxic responses in a systematic screening platform of this sort would require the use of more metabolically active primary human hepatic cells, rather than transformed cell lines. Our engineered human microlivers have been previously shown to satisfy this latter criterion, in that micropatterned co-cultures (MPCCs) of primary human hepatocytes and supportive stromal cells successfully maintain multiple axes of liver metabolism and function and have been shown to reliably predict the hepatoxicity of FDAapproved and preclinical compounds (Ballard et al., 2016; Davidson et al., 2017; Khetani and Bhatia, 2008; Khetani et al., 2013; Lin and Khetani, 2017; Wang et al., 2010; Ware et al., 2017) .
Here, we demonstrate that gene modulation of human hepatocytes can be effectively achieved in a robust, persistent manner in the MPCC system. Specifically, we exploited the endogenous RNA interference (RNAi) pathway to post-transcriptionally silence central drug metabolism genes and assess the impact of these changes on a natural substrate, as well as on DILI assessment of known hepatotoxins. By showing that it is possible to tune drug metabolism by directly manipulating gene expression patterns, we can better model populationwide diversity to screen for potential toxic compounds, or ''dial back'' key metabolizing pathways that could otherwise mask an effective candidate compound. This new capability can be used to open the door for structure-activity relationship testing of compounds in the setting of both high-and low-metabolizing genotypes. We also demonstrated that novel RNAi-based livertargeting therapies can be leveraged to model the effectiveness of two emerging alternatives to conventional chemical drugs, one that blocks the production of a toxic secreted protein, AAT, and another that removes a surface molecule required for entry by a hepatotropic pathogen, CD81. Collectively, this study highlights how genetic engineering tools can be applied to finetune in vitro human liver models to test and develop a wide range of pre-clinical interventions. It also provides a roadmap for the propagation of genetic manipulation of human hepatocytes to other engineered liver systems, such as 3D cultures, liver-ona-chip, and humanized mouse models.
RESULTS AND DISCUSSION
Engineered Human Microlivers Enable Robust LongTerm Nucleic Acid-Mediated Silencing An essential part of the drug development process is the analysis of hepatic metabolism of the candidate compound. Hepatic assays can be used to detect, avoid, and/or predict potential human liver toxicity as well as identify drugs with maximal efficacy. However, this practice has been hindered because the available systems do not adequately represent the diversity of human metabolic enzyme expression, nor do these culture systems maintain metabolic function over time. Previously, we have demonstrated that photolithography-based micropatterning and co-culture technologies are valuable tools that maintain primary human hepatocytes with stable hepatic-specific function for weeks (Khetani and Bhatia, 2008) (Figure 1 ). This platform has been engineered to accommodate 24-, 96-, and 384-well configurations (Gural et al., 2018; March et al., 2013 March et al., , 2015 . MPCCs have been widely used in pre-clinical and post-market testing to assess potential drug toxicity (Khetani et al., 2013; Kratochwil et al., 2017; Ware et al., 2015) . More recently, such systems have been used to model hepatotropic infections (Gural et al., 2017 (Gural et al., , 2018 March et al., 2013; Ng et al., 2014; Ploss et al., 2010; Shlomai et al., 2014) , enabling their use in screening for clinical-stage antimalarial drugs and vaccine efficacy (Kato et al., 2016; Kisalu et al., 2018; Phillips et al., 2015) . For the purposes of selecting optimally effective compounds, and for predicting DILI, any Fabrication of MPCCs involves a two-step process: first, patterning of collagen islands in multi-well plates using photolithography techniques, and second, seeding of primary human hepatocytes and stromal supportive fibroblasts to establish the coculture system. Patterned collagen islands (spots of 500 mm diameter; illustrations represent side and top views of the well) are obtained by applying a silicone elastomer polydimethylsiloxane (PDMS) mask to collagen (yellow)-coated wells, followed by exposure to oxygen plasma. Next, primary human hepatocytes (blue) are seeded and allowed to settle onto the collagen, creating patterned hepatocyte islands (top view). Nucleic acids (siRNA, green) are then included in the media and incubated for 20-24 h, after which mouse fibroblasts (pink) are seeded and allowed to bind in the intervening space between hepatocyte islands. Regular negatively charged siRNAs can be delivered to hepatocytes using cationic lipid transfection reagents, such as lipofectamine (orange). Chemically stabilized siRNAs conjugated to GalNAc are delivered to hepatocytes via interaction with the hepatocyte surface receptor, ASGPR. RNAi-induced gene silencing (light blue) efficiency can be assessed by multiple functional readouts (ELISA for secreted proteins, microscopy or flow cytometry for protein expression, RT-PCR for mRNA transcript abundance, or enzymatic cell assays) and challenged by different experimental perturbations, such as drugs or hepatotropic pathogens (e.g., Plasmodium parasites and hepatitis B or C viruses).
screening platform must not only utilize functionally stable human hepatocytes, but also take into account that varied expression of metabolizing enzymes will influence the dose at which a candidate therapeutic might elicit an effective and/or hepatotoxic response. Thus, screening assays must be performed with hepatocytes sourced from a wide range of genotypes, or-preferably, to enable interassay comparisons-assays should incorporate primary hepatocytes with tunable enzyme expression patterns, to reflect the diversity of human metabolism phenotypes. While modulation of metabolic enzymes has been attempted in short-term studies (Chan et al., 2018; Ramsden et al., 2014) , it has proven challenging to achieve robust and persistent modification of gene expression in human hepatocytes in vitro.
To assess whether MPCC-stabilized human hepatocytes could be successfully targeted for nucleic acid delivery to enable metabolic studies, we probed a major cytochrome P450 (CYP450) phase 1 enzyme, CYP3A4, involved in clinically relevant drug metabolism. Commercially available small interfering RNA (siRNA) oligonucleotide pools specific for CYP3A4 transcripts were delivered to human hepatocytes via transfection after seeding micropatterned hepatocytes. Scrambled siRNA sequences were added to additional wells as controls. Following overnight exposure to siRNA duplexes, supporting stromal fibroblasts were added to surround the islands of patterned primary hepatocytes, after which the cultures were maintained untreated, other than media changes, for the duration of the experiment ( Figure 1 ). CYP3A4 silencing efficiency was measured by qRT-PCR and detection of protein by immunofluorescence. Robust reduction of mRNA ( Figure 2A ) and protein ( Figure 2B ) was observed in the CYP3A4 siRNA-treated islands compared to control siRNA or untreated hepatocytes. To assess the impact of the observed protein loss on total enzymatic activity, we utilized a luminescence-based assay that specifically measures cellular CYP3A4 activity by converting a luminogenic substrate into luciferin, which is released into the culture media and further converted into light in the presence of luciferase ( Figure 2C ). Within 4 days of transfection, a 95% reduction in CYP3A4 activity was observed in the cultures treated with CYP3A4 siRNAs, relative to the untreated condition. No significant effect was detected in the wells transfected with the control siRNA ( Figure 2D ). While the degree of knockdown fell just short of 100%, we anticipate that the non-dividing status of the primary hepatocytes will minimize the risk that the residual population of unmodified cells will out-compete those that were successfully modified. To test this hypothesis, we evaluated the durability of the RNAi-induced CYP3A4 silencing by monitoring CYP3A4 enzymatic activity in the same wells over the course of several weeks. CYP3A4 activity levels remained at less than 30% of control samples for at least 20 days post-transfection ( Figure 2D ). In parallel, we also monitored the levels of secreted hepatocyte-specific biomarkers, such as human albumin, in all the tested conditions. As shown in Figure 2E , exposure to siRNAs (CYP3A4 or control) did not significantly change albumin production and secretion over the course of the culture period, suggesting that hepatocyte viability was not compromised. Additionally, levels of urea production were similarly unchanged ( Figure S1A ), and no obvious morphological alterations were observed in the various conditions (data not shown). Loss of CYP3A4 activity after RNAi-mediated silencing was further confirmed by exposure to a natural substrate, testosterone, which is mainly metabolized into 6b-hydroxytestosterone by this enzyme ( Figure S1B ) (Murayama et al., 2002; Waxman et al., 1988) . A short incubation with testosterone was sufficient to differentiate between the function of the CYP3A4 siRNA treated and controls, with a 50% reduction in 6b-hydroxytestosterone production and secretion ( Figure S1B ).
Next, we assessed the capability of the co-culture system to support the manipulation of multiple transcripts at the same time. siRNA oligonucleotides against CYP3A4 and CYP2D6 were added to micropatterned hepatocytes alone or in combination, and the extent and specificity of induced knockdown were determined by qRT-PCR and enzymatic assays. We observed highly specific and robust 80%-90% reduction of both CYP3A4 and CYP2D6 transcripts relative to the untreated or siRNA controls, when the two siRNAs were added simultaneously ( Figure 2F ). The silencing specificity was further corroborated by functional assays employing exposure to proluciferin ( Figure 2G ) or natural substrates ( Figure S1B ).
Nucleic Acid-Mediated Silencing Effectively Modifies Primary Human Hepatocyte Drug Metabolism
Having established that CYP450 activity can be effectively and durably inhibited by siRNA duplexes in primary human hepatocytes, we performed a proof-of-concept toxicity analysis, using known hepatotoxicants, acetaminophen and atorvastatin (Figure 3) . Acetaminophen (N-acetyl-p-aminophenol, APAP) is a widely used analgesic that can cause acute hepatic necrosis when administered at high doses, due to the formation of a toxic metabolite (N-acetyl-p-benzoquinone imine, NAPQI) produced when CYP3A4, CYP2E1, CYP1A2, and CYP2A6 act on the parent drug. NAPQI is detoxified by glutathione (GSH) to form an APAP-GSH conjugate, but sufficiently high doses of APAP can lead to 90% depletion of GSH, which results in binding of NAPQI to cellular macromolecules and induction of cell injury (James et al., 2003) (Figure 3A) . To evaluate whether siRNA-mediated CYP3A4 or CYP2E1 knockdown in human hepatocytes can blunt APAP toxicity, we assessed albumin secretion in drug-treated cultures with and without siRNAs against CYP3A4 or CYP2E1. Monitoring for reduced albumin production is one readout for hepatocyte damage (Ware et al., 2015) . One week after knockdown was initiated, MPCCs were treated with escalating doses of APAP for 24 h. An $2-fold increase of the half maximal inhibitory concentration (IC 50 ) of APAP was seen in CYP siRNA conditions compared to the control siRNA-treated cells ( Figures 3B,  3F, S1C) . Thus, by modifying the expression level of CYP3A4 or CYP2E1 enzymes, the toxicity of acute APAP treatment was reduced. To further demonstrate known mechanisms of action, we performed combinatorial experiments using siRNA treatment and a GSH-depleting agent, L-buthionine-sulfoximine (BSO). We observed increased APAP-induced hepatoxicity in the presence of BSO, which was considerably less pronounced when CYP3A4 activity was silenced ( Figures 3C and 3F) .
Next, we evaluated the CYP3A4-dependent metabolism and hepatoxicity of atorvastatin. This drug is primarily used as a lipid-depleting agent, owing to its capacity to inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Atorvastatin is metabolized by CYP3A4 forming ortho-and parahydroxylated metabolites ( Figure 3D ), and coadministration of CYP3A4 inhibiting drugs requires close monitoring to avoid increased statin exposure and increased risk of adverse drug reactions, including liver injury (Clarke and Mills, 2006) . While the mechanism underlying the atorvastatin-induced hepatotoxicity has not been established, it likely involves increased formation of reactive oxidative species during metabolism (Shu et al., 2016) . Using a similar experimental approach to that applied in the APAP studies above, we determined doseresponse curves to atorvastatin in human microlivers pre-treated with CYP3A4 or control siRNA. After 24 h incubation, we observed a right-shift of the albumin IC 50 curve in the CYP3A4 siRNA-treated compared to the control siRNA condition, thus confirming the CYP3A4-dependent mechanism ( Figures  3E and 3F ).
Our findings corroborate that co-cultured human hepatocytes are able to mediate functional knockdown of essential metabolizing enzymes, but also highlight the capacity to achieve robust and durable in vitro modulation of gene expression in these cells. Furthermore, by providing the drug discovery community with an engineered tool that enables the tuning of hepatic metabolism in primary human hepatocytes, this platform addresses an often overlooked and potentially counterintuitive challenge in the field. Namely, screening for new drug candidates in the presence of high-metabolizing hepatocytes can mask a potentially efficacious hit, in that if a toxic metabolite is produced, the otherwise non-toxic parent drug would be discarded. However, if it were possible to test the same drug in a setting of both high-and low-metabolizing hepatic cells, non-toxic parental drugs could be further optimized to bypass the CYP-dependent metabolic (E) Relative human albumin levels secreted in MPCCs, as determined by ELISA. Values (mean ± SEM, n = 2) were normalized to the corresponding untreated condition. See Figure S1A for urea levels.
(F) CYP3A4 and CYP2D6 mRNA levels at day 3 post-transfection with CYP3A4 and CYP2D6 siRNA duplexes, alone or in combination. Graph bars represent mean ± SEM (n = 3). p < 0.01. (G) Relative CYP3A4 activity in the same conditions as (F), using proluciferin. Graph bars represent mean ± SEM (n = 2). **p < 0.01. *p < 0.05. See Figure S1B for CYP3A4 activity measured with testosterone substrate.
conversion to an inactive, or even toxic compound. Whereas if the same screen were only conducted in low-metabolizing hepatocytes, the compound could fail in the clinic due to previously undetected DILI. In contrast, if only high-metabolizing cells were utilized, a potentially promising compound may be discarded. Current approaches include utilization of chemical inducers and inhibitors of CYP450 enzymes, but only a few compounds are available and they often lack specificity, thus affecting multiple enzymes. Moreover, these chemicals are only suitable for short-term studies, as they can cause dramatic toxicity. Therefore, the introduction of siRNA-mediated silencing to this in vitro system offers a simple and attractive alternative approach to query the mechanistic basis of metabolism and hepatoxicity during drug discovery, and the capacity to mimic patient-specific metabolism profiles without the need for a diverse portfolio of donor cells.
Nucleic Acid Targeting of Hepatocytes as a Candidate Drug Regimen
Nucleic acid therapeutics based on siRNAs are emerging as promising new class of drugs. Thus, we sought to explore whether in vitro liver models, such as human MPCC microlivers, might also serve as a screening platform to characterize siRNAs that target the liver. Until recently, nucleic acid delivery has been challenging, but with recent success in targeting siRNAs to the liver there is a need for powerful tools to identify and characterize the clinical utility of siRNAs. Recent reports have highlighted the encouraging clinical potential of targeting siRNA oligonucleotides for use in liver (Huang, 2017) . One such approach involves the covalent conjugation of chemically stabilized siRNA oligonucleotides to N-acetylgalactosamine (GalNAc) (Nair et al., 2014; Rajeev et al., 2015) , to enable high-affinity binding to the asialoglycoprotein receptor (ASGPR), which is highly expressed on the surface of hepatocytes. Following binding, GalNAc-modified siRNAs are taken up into the cytosol via clathrin-mediated endocytosis and are loaded into the RNA-induced silencing complex (RISC). As a first step in evaluating whether these modified siRNAs would be well-suited for screening using our engineered in vitro microlivers, we determined the expression levels of ASGPR, based on immunofluorescence staining of non-permeabilized hepatocytes, assayed at the time of siRNA addition (Figure S2A ). This assay represents an important step when using primary human hepatocyte-based microlivers for receptormediated interventions, since we have previously seen that not all human hepatocyte sources express equivalent protein levels and/or are similarly susceptible to receptor-mediated processes, such as infection (March et al., 2013; Shlomai et al., 2014) . Next, we assayed a set of GalNAc-conjugated and unconjugated siRNA molecules for their capacity to mediate gene silencing in MPCCs by free uptake. We tested siRNA duplexes specific to alpha-1 antitrypsin (AAT) (Ascha et al., 2015) . AATassociated liver disease is observed in patients expressing a mutant AAT allele that results in AAT protein misfolding, aggregation, and accumulation. By knocking down AAT in patients Values (mean ± SEM) were normalized to drug-free control wells on each condition (CYP2E1 siRNA, n = 2; CYP3A4 siRNA, n = 5; control siRNA, n = 5; control siRNA + BSO, n = 2; CYP3A4 siRNA + BSO, n = 2). See Figure S1C for CYP2E1 knockdown efficiency.
(D and E) Schematic of atorvastatin metabolism (D) and albumin levels in MPCCs exposed for 24 h to atorvastatin on day 6 post-transfection (E). Normalized data represent mean ± SEM (n = 2).
(F) Summary of IC 50 values (mean ± SD) for APAP (left) and atorvastatin (right) in the various conditions. IC 50 was calculated using non-linear regression variable slope (normalized) analysis.
with the genetic defect, their liver burden could be reduced significantly. We observed a robust dose-and GalNAc-dependent decrease in secreted AAT ( Figures 4A and S2B ) from normal, primary human hepatocytes, suggesting efficient uptake of the modified AAT siRNA molecules in the absence of transfection reagent. Similar to what has been reported in preclinical and clinical trials, we observed that GalNAc siRNA-mediated silencing is sustained for several weeks in our in vitro system ( Figure 4A ). Consistent hepatocyte viability was observed when using secreted albumin as a proxy for hepatocyte health ( Figure 4B ). Collectively, these findings highlight that it is possible to leverage engineered human microlivers to test the efficacy, and potentially also the risk of toxicity, of clinically relevant GalNAc-decorated siRNA oligonucleotides. From a translational perspective, the availability of such a validated screening tool to use in vitro, prior to advancing to clinical development, is an unquestionable alternative to animal models that are currently employed to down-select hepatotoxic GalNAcconjugated siRNAs (Janas et al., 2018) .
Leveraging Nucleic Acid-Mediated Silencing to Intervene in Hepatotropic Infections
The liver is targeted by numerous infectious pathogens that use the hepatocyte as an entry point and site of massive replication in human hosts. To explore the potential therapeutic application of GalNAc siRNA conjugates in preventing or treating hepatotropic infections, we turned to CD81, a tetraspanin integral membrane protein expressed by hepatocytes and required for malariacausing parasites Plasmodium falciparum to enter into their human host (Manzoni et al., 2017; Silvie et al., 2003) . First, we confirmed by immunofluorescence staining of non-permeabilized cells that CD81 siRNA-GalNAc conjugates added to patterned human hepatocytes in free uptake mode resulted in robust depletion of CD81 protein on the surface of hepatocytes, relative to the GalNAc-free CD81 siRNA, GalNAcconjugated AAT siRNA, or untreated control wells ( Figures 4C  and 4D ). Next, we infected the pre-treated hepatocytes with P. falciparum parasites freshly isolated from infected mosquitoes. In parallel, we treated control wells with a known liveracting antimalarial drug, primaquine. In previous work, we have demonstrated that MPCCs enable full 7-day liver-stage development of P. falciparum parasites, leading to replication and formation of new infectious parasites, which can then infect human erythrocytes, mimicking a natural infection (March et al., 2013 Ng et al., 2014) . To determine the impact of GalNAc-conjugated CD81 siRNA treatment, we employed fluorescence microscopy and used parasite-specific markers to quantify the number of infected hepatocytes and measure the area occupied by intracellular parasite, as a proxy for parasite development, at 4 days post-infection. We observed an 80% reduction in the number of parasites present in wells treated with GalNAcconjugated CD81 siRNA, similar to the impact of primaquine treatment ( Figures 4E-4G) , though the few parasites that were detected within the cultures did not exhibit a reduction in their development. Unconjugated CD81 siRNA or siRNA GalNAcconjugates against an irrelevant sequence (AAT) elicited no significant change in the infection by malaria parasites relative to the untreated controls ( Figure 4F ). Collectively, these results support the relevance of applying engineered liver models, such as MPCC, as screening and discovery tools to test the utility of GalNAc-conjugated siRNA molecules for the treatment or prophylaxis of liver diseases.
Conclusion
The complexity of human physiology has historically made it challenging to design new drugs that are efficacious yet induce minimal toxicity. The biology of the human liver has made the drug discovery process even more challenging, given the multitude of essential functions this organ serves, and the speciesspecific and context-specific behavior of its hepatocytes. A wide variety of engineering tools have been brought to bear in the effort to establish culture conditions that make human hepatocyte studies amenable to scaled-up screening, while still maintaining their essential functional output. In this study, we explored the capacity to manipulate gene expression in primary human hepatocytes by employing various RNAi-based agents and delivery systems. We demonstrated robust and durable gene silencing of essential hepatic metabolizing enzymes, intracellular pathological proteins, and surface molecules that permit infection by liver pathogens using a 2D-engineered micropatterned co-culture system. This work validated RNAi as an approach not only to study primary human hepatocytes, but also to assess hepatic-targeted nucleic acid agents, and achieve direct modification of drug metabolism. In so doing, we envision a path to enable more accurate and efficient identification of promising chemical compounds and small molecule drugs by detecting potential toxic reactions elicited by both parent and metabolized drug products, as well as the capacity to mimic patient-specific metabolism profiles without the need for a diverse portfolio of donor cells. Finally, we believe the impact of this study will extend beyond RNAi to other nucleic acid tools and therapies (e.g., adeno-associated viral delivery) for which there are not currently adequate human model systems, and expect that these collective genetic tools could likewise be extended to other engineered liver models in the future.
Limitations of Study
We acknowledge that the work presented here only addresses the use of a single form of nucleic acids, siRNA, and also that we have thus far only examined reduction in gene expression, rather than presenting efforts to overexpress a gene of interest. Furthermore, the reduction we observe does not achieve full knockdown, and thus if either complete deletion of a gene were desired or if a protein with a faster turnover rate were under investigation, an alternate approach to gene modification may be more appropriate. Finally, in the experiments described above, the highest efficiency was obtained when silencing of human hepatocyte gene expression was induced prior to the formation of the co-culture platform, i.e., when siRNA agents were added to hepatocyte-only cultures. Thus, kinetic experiments designed to query the impact of silencing in established MPCC cultures would not be supported by the standard platform, without additional modifications that we are currently exploring.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
